Inhibitex to Participate in Four Upcoming Investor Conferences
November 09 2011 - 9:23AM
Business Wire
Inhibitex, Inc. (NASDAQ:INHX), a biopharmaceutical company
focused on developing products to treat and prevent serious
infectious diseases, announced that Russell H. Plumb, President and
Chief Executive Officer, is scheduled to present an overview of the
company and its pipeline of differentiated antiviral compounds at
the following three investor conferences in November:
-- 2011 Credit Suisse Healthcare Conference on November 10, 2011
at 10:00 AM MST. The conference is being held at the Arizona
Biltmore Resort Hotel & Spa in Phoenix, Arizona.
-- Lazard Capital Markets 8th Annual Healthcare Conference on
November 16, 2011 at 2:30 PM EST. The conference is being held at
The Pierre Hotel in New York, NY. The presentation will be
simultaneously webcast and can be accessed by visiting the
Investors section of the Inhibitex website
at www.inhibitex.com. Shortly following the live webcast a
replay will also be available on the Company website.
--23rd Annual Piper Jaffray Health Care Conference on November
30, 2011 at 1:00 PM EST. The conference is being held at The New
York Palace hotel in New York, NY.
Mr. Plumb will also be attending the Brean Murray, Carret &
Co. 2011 Life Sciences Summit on November 14, 2011. The conference
is being held at the Grand Hyatt Hotel in New York, NY. There are
no presentations at this conference.
About Inhibitex
Inhibitex, Inc. is a biopharmaceutical company focused on
developing products to prevent and treat serious infectious
diseases. The Company’s clinical-stage pipeline currently includes
two Phase 2 development programs; INX-189, a nucleotide polymerase
inhibitor in development for the treatment of chronic hepatitis C
infections and FV-100, a nucleoside analogue in development for the
treatment of shingles-associated pain. The Company also has other
HCV nucleotide polymerase inhibitors in preclinical development and
has licensed the use of its proprietary MSCRAMM® protein platform
to Pfizer for the development of a staphylococcal vaccine, which is
currently being evaluated in a Phase 1/2 clinical trial.
For additional information about the Company, please visit
www.inhibitex.com.
Inhibitex, Inc. (MM) (NASDAQ:INHX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Inhibitex, Inc. (MM) (NASDAQ:INHX)
Historical Stock Chart
From Jul 2023 to Jul 2024